CalciMedica, Inc. CALC
We are a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates target calcium release-activated calcium ("CRAC") channels and, if approved, would represent a new class of therapeutics.
Clinical and preclinical data suggest that inhibition of CRAC channels may have therapeutic potential through a dual mechanism involving modulation of inflammatory signaling and protection of tissue cells from calcium-mediated injury. Dysregulated CRAC channel signaling has been implicated in a range of acute and chronic diseases characterized by immune activation, inflammation, and cellular injury. We seek to leverage our CRAC channel inhibitor platform to develop therapies for indications in which these pathways are clinically relevant.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $15.2M | $14.5M | $15.9M | $8.3M | $18.9M | $21.0M | $30.6M | — |
| SG&A | $7.9M | $9.7M | $22.2M | $5.8M | $17.0M | $8.9M | $6.9M | — |
| Total operating expenses | $23.1M | $24.2M | $38.1M | $14.2M | $35.9M | $29.8M | $37.5M | — |
| Operating income | -$23.1M | -$24.2M | -$38.1M | -$14.2M | -$35.9M | -$29.8M | -$37.5M | — |
| Interest expense | $1.4M | $0 | — | — | — | — | — | — |
| Pre-tax income | -$29.6M | -$13.7M | -$34.4M | -$7.8M | — | — | — | — |
| Income tax | $0 | $0 | $1.0K | $1.0K | — | — | — | — |
| Net income | -$29.6M | -$13.7M | -$34.4M | -$7.8M | -$35.8M | -$27.5M | -$37.0M | — |
| EPS, basic | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 | — | — | — |
| EPS, diluted | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 | -5.25 | -33.41 | — |
| Shares, diluted (wtd. avg.) | 15.0M | 11.2M | 4.5M | 82,245 | 21.2M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.5M | $7.9M | $5.5M | $1.3M | $13.4M | $33.4M | $15.9M | — |
| Short-term investments | $1.5M | $10.7M | $5.7M | $0 | $50.3M | $61.6M | $20.1M | — |
| Total current assets | $13.5M | $19.7M | $11.6M | $1.7M | $67.1M | $99.2M | $36.3M | — |
| Property, plant and equipment | $50.0K | $119.0K | $167.0K | $147.0K | $2.0M | $1.9M | $2.0M | — |
| Total assets | $13.6M | $19.8M | $12.2M | $3.3M | $69.1M | $101.8M | $40.7M | — |
| Accounts payable | $1.2M | $2.0M | $1.4M | $2.9M | $527.0K | $2.5M | $4.6M | — |
| Total current liabilities | $3.8M | $3.7M | $4.0M | $4.8M | $4.1M | $7.0M | $12.3M | — |
| Total liabilities | $20.2M | $5.4M | $4.0M | $12.6M | $4.1M | $7.0M | $12.3M | — |
| Retained earnings | -$189.3M | -$159.8M | -$146.1M | -$111.7M | -$169.2M | -$133.4M | -$105.8M | — |
| Total equity | -$6.6M | $14.4M | $8.2M | -$71.3M | -$64.0M | $94.8M | -$103.0M | -$66.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.2M | -$21.1M | -$25.7M | -$11.8M | -$31.5M | -$32.1M | -$31.2M | — |
| Depreciation and amortisation | $46.0K | $58.0K | $58.0K | $52.0K | $519.0K | $395.0K | $303.0K | — |
| Stock-based compensation | $3.0M | $2.3M | $12.0M | $1.8M | $5.4M | $1.8M | $738.0K | — |
| Capital expenditure | $28.0K | $8.0K | $78.0K | $4.0K | $488.0K | $1.0M | $605.0K | — |
| Investing cash flow | $9.6M | -$4.4M | $8.9M | -$4.0K | $10.8M | -$42.6M | -$20.6M | — |
| Financing cash flow | $15.2M | $28.0M | $20.9M | $8.5M | $695.0K | $92.2M | $54.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-314085.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$37.0M | -$27.5M | -$35.8M | -$7.8M | -$34.4M | -$13.7M | -$29.6M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Unregistered share sale Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |